Methylphenidate and Emgality drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Methylphenidate (methylphenidate) and Emgality (galcanezumab-gnlm). Common drug interactions include suicide attempt among females and anhedonia among males.

The phase IV clinical study analyzes what interactions people have when they take Methylphenidate and Emgality. It is created by eHealthMe based on reports of 15 people who take the same drugs from the FDA, and is updated regularly.

What is Methylphenidate?

Methylphenidate has active ingredients of methylphenidate. eHealthMe is studying from 8,216 Methylphenidate users. Check the latest studies of Methylphenidate.

What is Emgality?

Emgality has active ingredients of galcanezumab-gnlm. eHealthMe is studying from 24,702 Emgality users. Check the latest studies of Emgality.

On Jul, 14, 2026

15 people who take Methylphenidate and Emgality together, and have interactions are studied.

Methylphenidate and Emgality drug interactions.

What are the common drug interactions of Methylphenidate and Emgality, by gender? *:

female:

Suicide attempt
Gastrointestinal disorder (functional problems of gastrointestinal tract)
Abscess (pus)
Injection site pain
Interstitial lung disease
Malaise (a feeling of general discomfort or uneasiness)
Narcolepsy (brain's inability to regulate sleep-wake cycles normally)
Stress
Abdominal pain
Alopecia (absence of hair from areas of the body)

male:

Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Vitamin d deficiency
Chronic kidney disease
Depression
Emotional distress
Fanconi syndrome acquired (self developed genetic disease of kidney damage due to defective transport system)
Osteonecrosis (death of bone)
Osteopenia (a condition where bone mineral density is lower than normal)
Pain

What are the common drug interactions of Methylphenidate and Emgality, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Cardiovascular disorder (heart diseases)
Injection site bruising
Injection site pain

30-39:

Alopecia (absence of hair from areas of the body)

40-49:

Malaise (a feeling of general discomfort or uneasiness)
Abdominal pain
Abscess (pus)
Colonoscopy
Diarrhoea
Dyspnoea (difficult or laboured respiration)
Exposure to communicable disease
Injection site erythema (redness at injection site)
Injection site pruritus (severe itching at injection site)
Injection site swelling

50-59:

Suicide attempt
Interstitial lung disease
Narcolepsy (brain's inability to regulate sleep-wake cycles normally)
Gastrointestinal disorder (functional problems of gastrointestinal tract)
Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures)
Injection site pain
Migraine (headache)
Wrist fracture

60+:

Fibromyalgia (a long-term condition which causes pain all over the body)

What are the existing conditions these people have? *

Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 5 people, 33.33%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 4 people, 26.67%
Migraine (headache): 4 people, 26.67%
High Blood Cholesterol: 2 people, 13.33%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 2 people, 13.33%
Asthma: 2 people, 13.33%
High Blood Pressure: 2 people, 13.33%
Depression: 2 people, 13.33%
Diarrhea: 1 person, 6.67%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Methylphenidate and Emgality?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously